The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K.
Radar 95 (high attention) · dilution pressure high · listing risk high · governance risk low · runway 2.6 mo · strongest signal: Exchange deficiency notice (Aug 28, 2026)
What would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
What would prove it wrong: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.
Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.
The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Cash need (runway < 6 months) coexists with live selling machinery (equity line, pipe, shelf filed, warrant inducement). Base case is a discounted raise; the question is when, not if.
Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25. Exchange deficiency plus a structural reason cure is hard (sub-$5M float, negative equity, no cash, or a reverse split already used). Under Nasdaq's 2026 rules (one reverse split per 12 months; $5M MVLS floor with no cure period from Sept 2026) the usual escape hatches are narrower.
Variable-priced paper is outstanding while the listing is under stress — the structure where dilution can accelerate. Watch the share count each quarter. Discount-priced or variable-priced securities are outstanding while the company is managing its listing with reverse splits/notices. Each conversion lowers the price, which lowers the next conversion price.
On August 28, 2026, GeoVax disclosed a Nasdaq Staff determination of non-compliance with stockholders' equity requirements and requested a hearings panel (8-K filed 16:16 ET). The company also executed an equity-line agreement and warrant inducement on August 25-27, 2026 (8-K filed 16:09 ET). As of June 30, 2026, the company held $3.1 million in cash against a ~$14.6 million annualized burn rate, implying approximately 2.6 months of runway (10-Q as of June 30, 2026).
Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 80 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.
Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.
| Date | Signal | Evidence | Score |
|---|---|---|---|
| Sep 17, 2026 | ▼ Shelf filed | S-1 filed 2026-09-17 filing | 30 |
| Sep 10, 2026 | ▼ Hearings panel | “hearings panel” language in 8-K (EX-99.1) filed 2026-09-10 filing | 51 |
| Sep 10, 2026 | ▼ Minimum bid deficiency | “min bid” language in 8-K (EX-99.1) filed 2026-09-10 filing | 42 |
| Sep 10, 2026 | ▼ Delisting language | “delisting notice” language in 8-K (EX-99.1) filed 2026-09-10 filing | 32 |
| Sep 10, 2026 | ▼ Reverse split | “reverse split” language in DEF 14A (DEF 14A) filed 2026-09-10 filing | 29 |
| Aug 31, 2026 | ▼ Reverse split | “reverse split” language in PRE 14A (PRE 14A) filed 2026-08-31 filing | 29 |
| Aug 28, 2026 | ▼ Exchange deficiency notice | 8-K Item 3.01 filed 2026-08-28 (accepted 16:16 ET) filing | 59 |
| Aug 28, 2026 | ▼ Hearings panel | “hearings panel” language in 8-K (8-K) filed 2026-08-28 filing | 58 |
| Aug 28, 2026 | ▼ Equity deficiency | “stockholders equity deficiency” language in 8-K (8-K) filed 2026-08-28 filing | 52 |
| Aug 28, 2026 | ▼ Equity line | “equity line” language in 8-K (EX-10.1) filed 2026-08-28 filing | 52 |
| Aug 28, 2026 | ▼ Minimum bid deficiency | “min bid” language in 8-K (8-K) filed 2026-08-28 filing | 48 |
| Aug 28, 2026 | ▼ Delisting language | “delisting notice” language in 8-K (8-K) filed 2026-08-28 filing | 46 |
| Aug 28, 2026 | ▼ Warrant inducement | “warrant inducement” language in 8-K (EX-99.1) filed 2026-08-28 filing | 43 |
| Aug 28, 2026 | ▼ Unregistered sale | 8-K Item 3.02 filed 2026-08-28 (accepted 16:09 ET) filing | 35 |
| Aug 28, 2026 | ▼ Reverse split | “reverse split” language in 8-K (8-K) filed 2026-08-28 filing | 34 |
| Aug 28, 2026 | ▼ Reverse split | “reverse split” language in 8-K (EX-4.1) filed 2026-08-28 filing | 34 |
| Aug 28, 2026 | ▼ PIPE | “pipe” language in 8-K (EX-4.1) filed 2026-08-28 filing | 33 |
| Aug 28, 2026 | ▼ Delisting language | “delisting notice” language in 8-K (EX-10.1) filed 2026-08-28 filing | 32 |
| Jun 30, 2026 | ▼ Share count +25% | Shares outstanding 3,473,260 (2026-05-14) -> 7,369,243 (2026-07-27), +112% filing | 40 |
| Jun 30, 2026 | ▼ Runway < 6 months | ~2.6 months runway: liquidity $3,143,422 as of 2026-06-30, burn $14,591,532/yr (annualized 180-day YTD operating cash flow [companyfacts]) filing | 40 |
AUID authID Inc. · SOBR SOBR Safe, Inc. · SDST Stardust Power Inc. · ADIL ADIAL PHARMACEUTICALS, INC. · MYSZ My Size, Inc. · SNTI Senti Biosciences Holdings, · screener →